TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03343392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetam/ketoro tromet group
Description: One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
Study: NCT00794495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study: NCT00375557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex ER
Description: Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
Study: NCT03915808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid group
Description: supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil group
Description: supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
Study: NCT04169087

Intervention type: OTHER
Intervention: QoR-15
Description: The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
Study: NCT02960178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based training
Description: Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking training
Description: Over-ground practice of stepping and balance tasks in standing. One hour in duration.
Study: NCT01671020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
Study: NCT02053909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study: NCT04115579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit 1 Control
Description: Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit 2 Test
Description: Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
Study: NCT00558155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peptisorb
Description: standard isocaloric eteral diet (1 ml = 1 kcal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stresson
Description: Oligopeptic, enteral diet (1 ml=1.25 kcal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven, Dipeptiven
Description: Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Study: NCT01587378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Study: NCT02616757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight Omnisense Quantitative Ultrasound
Description: Ultrasound

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sunlight Omnisense Quantitative Ultrasound
Description: Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight Omnisense Quantitative Ultrasound
Description: Ultrasound
Study: NCT03029741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0284
Description: Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD0284
Description: Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
Study: NCT03426293

Intervention type: OTHER
Intervention: Measuring the ACT to determine effect of heparin
Description: Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
Study: NCT02248948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides
Description: Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
Study: NCT01468220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Endurance training three times per week over six weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance training
Description: Endurance training three times per week over six weeks
Study: NCT00283049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin glargine administered subcutaneously once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin glargine administered subcutaneously once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin glargine administered subcutaneously once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
Study: NCT00886704

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)
Description: Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)
Description: Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control convenience drink
Description: Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
Study: NCT01068197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Load Diet versus Low Fat Diet
Description: We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet versus Low Fat Diet
Description: We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years.
Study: NCT02256605

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D-3
Description: Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D-3
Description: Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
Study: NCT04541290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic 0.1 % Topical Ointment
Description: Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
Study: NCT01033526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Acetylsalicylic acid, BAYE4465)
Description: 1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
Study: NCT00350584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Telehealth Intervention
Description: Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Telehealth Intervention
Description: Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
Study: NCT01022996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
Study: NCT03975270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and Nab-paclitaxel
Description: Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
Study: NCT00998049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor 160mg/kg/dose by IV on days 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
Study: NCT02728661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE
Description: PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed PACE
Description: Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
Study: NCT03433495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Melodic Intonation Therapy
Study: NCT03228303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150 MG [Tasigna]
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400mg
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study: NCT05187052

Intervention type: OTHER
Intervention: Tracheal intubation
Description: Video-assisted intubation technique

Intervention type: OTHER
Intervention: Tracheal intubation
Description: Video-assisted intubation technique

Intervention type: OTHER
Intervention: Tracheal intubation
Description: Video-assisted intubation technique
Study: NCT02018406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination injection of EPO and G-CSF
Description: Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of normal saline
Description: Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
Study: NCT03887845

Intervention type: PROCEDURE
Intervention: Surgery
Description: The respective surgical approach for any gastric and colorectal surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: The respective surgical approach for any gastric and colorectal surgery
Study: NCT02251379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus
Description: Inhaled corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus
Description: Inhaled corticosteroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Environmental Intervention
Description: Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus
Description: inhaled corticosteroids + long-acting beta agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus
Description: inhaled corticosteroids + long-acting beta agonist
Study: NCT02518451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg film-coated caplets (test formulation)
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg film-coated caplets (reference formulation)
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Study: NCT02982369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain Education
Description: Subjects will receive pain education based in biopsychosocial approach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education
Description: Subjects will receive pain education based in biopsychosocial approach

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
Study: NCT05092178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: calorie restricted diet and exercise
Description: The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise alone
Description: In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
Study: NCT03066908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys® Lacrimal Stent
Description: Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
Study: NCT01753583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: High-resolution OCT imaging of the cornea

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: High-resolution OCT imaging of the cornea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slit lamp biomicroscopy
Description: Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slit lamp biomicroscopy
Description: Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
Study: NCT04332224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanketrol cooling device and water-perfused blankets
Description: Blanketrol and water-perfused blankets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanketrol and Kool Kit
Description: Blanketrol cooling device with water-perfused vest, hood and lower body blanket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: Arctic Sun cooling device with gel cooling pads
Study: NCT03385720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified neck dissection
Description: Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional neck dissection
Description: traditional neck dissection without preservation of submandibular gland
Study: NCT04346498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest-to-back

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chest-to-back
Study: NCT03305289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed Radiofrequency
Description: sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thermal Radiofrequency
Description: sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds